The role of 18F-FDG-PET/CT in the management of differentiated thyroid cancer
Loading...
Files
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Wolters Kluwer Health
Abstract
Introduction In previous literature, 18F-FDG-PET/ CT imaging significantly impacted differentiated thyroid cancer (DTC) therapy. Low thyroglobulin (Tg) levels and negative Iodine-131 (131I) whole-body scan (WBS), along with negative 18F-FDG-PET/ CT, suggested a lesser likelihood of active illness. Positive 18F-FDG-PET/CT findings, however, were associated with a variety of signs of local recurrence and regional or distant metastases in patients with suspected WBS. We aim to evaluate the utility of 18F-FDG-PET/CT in managing DTC patients with negative 131I post-therapy WBS and elevated Tg. Material and methods We retrospectively reviewed 55 patients with DTC (76% papillary and 24% follicular). Patients underwent total thyroidectomy or several radioactive iodine (RAI) treatments or both. WBS was performed 5–7 days after RAI treatment. Inclusion criteria were elevated serum Tg, negative anti-Tg auto-antibodies (AbTg) during long-term follow-up, presence of 18F-FDG-PET/CT images, and negative or suspicious WBS. Results 54% of 18F-FDG-PET/CTs detected at least one lesion, mainly, cervical lymph nodes (49.9%), mediastinal lymph nodes (40.4%), local recurrence (34%), and bone or tissue metastasis (36.2%). The three major sites of metastasis were lung, bone, and liver. 18F-FDG-PET/CT identified recurrence or metastasis in 45% of patients with high serum Tg and negative WBS, modifying therapeutic management in half the patients for suitable treatment modality (surgery vs. tyrosine kinase inhibitor). Conclusion The findings redemonstrate that elevated Tg with negative or suspicious WBS necessitates 18F-FDG-PET/CT for localization of recurrence.18F-FDG-PET/CT is useful in managing locally recurrent or metastatic DTC with high Tg levels. It influences treatment and accurately assesses disease severity. Nucl Med Commun 44: 1046–1052 Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved. © 2023 Lippincott Williams and Wilkins. All rights reserved.
Description
Keywords
18f-fdg pet/ct, Differentiated thyroid cancer, Radioactive iodine, Thyroglobulin, Whole body scan, Fluorodeoxyglucose f 18, Glucose, Iodine 131, Protein tyrosine kinase inhibitor, Thyroglobulin antibody, Adult, Aged, Article, Bone metastasis, Cancer recurrence, Cervical lymph node, Cervical lymph node metastasis, Controlled study, Diagnostic accuracy, Diagnostic test accuracy study, Disease activity, Disease severity, Female, Follow up, Glucose blood level, Human, Liver metastasis, Lung metastasis, Lymph node metastasis, Major clinical study, Male, Maximum standardized uptake value, Mediastinum lymph node, Middle aged, Positron emission tomography-computed tomography, Radioisotope therapy, Retrospective study, Supraclavicular lymph node, Thyroglobulin blood level, Thyroid follicular carcinoma, Thyroid papillary carcinoma, Total thyroidectomy, Whole body scintiscanning